Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Total Current Liabilities (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Total Current Liabilities for 6 consecutive years, with $18.7 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 48.01% to $18.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.7 million through Dec 2025, down 48.01% year-over-year, with the annual reading at $18.7 million for FY2025, 48.01% down from the prior year.
  • Total Current Liabilities for Q4 2025 was $18.7 million at TScan Therapeutics, down from $29.2 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $38.6 million in Q2 2024, with the low at $14.0 million in Q1 2023.
  • Average Total Current Liabilities over 5 years is $25.8 million, with a median of $28.7 million recorded in 2024.
  • The sharpest move saw Total Current Liabilities surged 124.1% in 2024, then plummeted 48.01% in 2025.
  • Over 5 years, Total Current Liabilities stood at $21.3 million in 2021, then decreased by 18.92% to $17.3 million in 2022, then skyrocketed by 72.32% to $29.8 million in 2023, then rose by 20.58% to $36.0 million in 2024, then tumbled by 48.01% to $18.7 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $18.7 million, $29.2 million, and $31.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.